| Product Code: ETC7657189 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Non-Small Cell Lung Cancer Diagnostics Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Non-Small Cell Lung Cancer Diagnostics Market - Industry Life Cycle |
3.4 Israel Non-Small Cell Lung Cancer Diagnostics Market - Porter's Five Forces |
3.5 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.6 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.7 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume Share, By Test, 2021 & 2031F |
3.8 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume Share, By End-User, 2021 & 2031F |
4 Israel Non-Small Cell Lung Cancer Diagnostics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence and prevalence of non-small cell lung cancer in Israel |
4.2.2 Technological advancements leading to the development of more accurate and efficient diagnostic tools |
4.2.3 Growing awareness about the importance of early detection and diagnosis of lung cancer |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of diagnostic tests in Israel |
4.3.2 High cost associated with advanced diagnostic technologies |
4.3.3 Limited access to healthcare facilities and diagnostic services in certain regions of Israel |
5 Israel Non-Small Cell Lung Cancer Diagnostics Market Trends |
6 Israel Non-Small Cell Lung Cancer Diagnostics Market, By Types |
6.1 Israel Non-Small Cell Lung Cancer Diagnostics Market, By Cancer Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Cancer Type, 2021- 2031F |
6.1.3 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Lung Adenocarcinoma (LUAD), 2021- 2031F |
6.1.4 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Lung Squamous Cell carcinoma (LUSC), 2021- 2031F |
6.1.5 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Large Cell Carcinoma, 2021- 2031F |
6.1.6 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Non-Small Cell Lung Cancer Diagnostics Market, By Product |
6.2.1 Overview and Analysis |
6.2.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Reagents & Kits, 2021- 2031F |
6.2.3 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Instruments And Services & Softwares, 2021- 2031F |
6.3 Israel Non-Small Cell Lung Cancer Diagnostics Market, By Test |
6.3.1 Overview and Analysis |
6.3.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Imaging Test, 2021- 2031F |
6.3.3 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Molecular Test, 2021- 2031F |
6.3.4 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Biopsy, 2021- 2031F |
6.3.5 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Sputum Cytology, 2021- 2031F |
6.3.6 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Thoracentesis, 2021- 2031F |
6.3.7 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Immunohistochemistry, 2021- 2031F |
6.4 Israel Non-Small Cell Lung Cancer Diagnostics Market, By End-User |
6.4.1 Overview and Analysis |
6.4.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Hospital, 2021- 2031F |
6.4.3 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Clinical Laboratories, 2021- 2031F |
6.4.4 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Academics, 2021- 2031F |
6.4.5 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Non-Small Cell Lung Cancer Diagnostics Market Import-Export Trade Statistics |
7.1 Israel Non-Small Cell Lung Cancer Diagnostics Market Export to Major Countries |
7.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Imports from Major Countries |
8 Israel Non-Small Cell Lung Cancer Diagnostics Market Key Performance Indicators |
8.1 Average time taken from diagnosis to treatment initiation for non-small cell lung cancer patients in Israel |
8.2 Adoption rate of novel diagnostic technologies in lung cancer diagnosis |
8.3 Survival rates of non-small cell lung cancer patients in Israel |
8.4 Number of accredited healthcare facilities offering non-small cell lung cancer diagnostic services |
9 Israel Non-Small Cell Lung Cancer Diagnostics Market - Opportunity Assessment |
9.1 Israel Non-Small Cell Lung Cancer Diagnostics Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Opportunity Assessment, By Product, 2021 & 2031F |
9.3 Israel Non-Small Cell Lung Cancer Diagnostics Market Opportunity Assessment, By Test, 2021 & 2031F |
9.4 Israel Non-Small Cell Lung Cancer Diagnostics Market Opportunity Assessment, By End-User, 2021 & 2031F |
10 Israel Non-Small Cell Lung Cancer Diagnostics Market - Competitive Landscape |
10.1 Israel Non-Small Cell Lung Cancer Diagnostics Market Revenue Share, By Companies, 2024 |
10.2 Israel Non-Small Cell Lung Cancer Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here